Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. doi:10.3322/caac.2120824399786
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China 2011. Chin J Cancer Res. 2015;27:2. doi:10.1186/s40880-015-0001-225717220
   PubMed Web of Science ®Google Scholar
• Besse B, Adjei A, Baas P, et al. 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25:1475–1484. doi:10.1093/annonc/mdu12324669016
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–222. doi:10.1016/S1470-2045(13)70604-124439929
   PubMed Web of Science ®Google Scholar
• John G, Christina L, Ellis PM, Ung YC, Evans WK. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol. 2010;5:260–274. doi:10.1097/JTO.0b013e3181c6f03520101151
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4. J Natl Compr Canc Netw. 2016;14:255. doi:10.6004/jnccn.2016.003126957612
   PubMed Web of Science ®Google Scholar
• Reinhard B, Jürgen W, Thomas RK, et al. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol. 2013;31:1858–1865. doi:10.1200/JCO.2012.45.986723589544
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006;11:190–198. doi:10.1007/s10147-006-0583-416850125
   PubMed Web of Science ®Google Scholar
• Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008;99:1757–1762. doi:10.1038/sj.bjc.660472118985035
   PubMed Web of Science ®Google Scholar
• Mello RAD, Escriu C, Castelobranco P, et al. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget. 2018;9:11805–11815. doi:10.18632/oncotarget.2366829545937
   PubMedGoogle Scholar
• Batson S, Mitchell SA, Windisch R, et al. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther. 2017;10:2473–2482. doi:10.2147/OTT28503070
   PubMed Web of Science ®Google Scholar
• Lee J-K, Hahn S, Kim D-W, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311:1430–1437. doi:10.1001/jama.2014.331424715074
   PubMed Web of Science ®Google Scholar
• Lim E-A, Lee H, Bae E, et al. Economic evaluation of companion diagnostic testing for EGFR mutations and first-line targeted therapy in advanced non-small cell lung cancer patients in South Korea. PLoS One. 2016;11:e0160155. doi:10.1371/journal.pone.016015527483001
   PubMed Web of Science ®Google Scholar
• Schremser K, Rogowski WH, Adler-Reichel S, et al. Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics. 2015;33:1215–1228. doi:10.1007/s40273-015-0305-826081300
   PubMed Web of Science ®Google Scholar
• Lu S, Ye M, Ding L, et al. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget. 2017;8:9996–10006. doi:10.18632/oncotarget.1431028036283
   PubMedGoogle Scholar
• Narita Y, Matsushima Y, Shiroiwa T, et al. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer. 2015;90:71–77. doi:10.1016/j.lungcan.2015.07.00626259876
   PubMed Web of Science ®Google Scholar
• Kumar G, Woods B, Hess LM, et al. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the US. Lung Cancer. 2015;89:294–300. doi:10.1016/j.lungcan.2015.05.02026122345
   PubMed Web of Science ®Google Scholar
• Vergnenegre A, Massuti B, De Marinis F, et al. Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC. J Thorac Oncol. 2016;11:801–807. doi:10.1016/j.jtho.2016.02.00426899757
   PubMed Web of Science ®Google Scholar
• Lee VW, Schwander B, Lee VH. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. Hong Kong Med J. 2014;20:178–186. doi:10.12809/hkmj13398624281768
   PubMed Web of Science ®Google Scholar
• Zhu J, Li T, Wang X, et al. Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis. BMC Cancer. 2013;13:39. doi:10.1186/1471-2407-13-3923360224
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–151. doi:10.1016/S1470-2045(14)71173-825589191
   PubMed Web of Science ®Google Scholar
• Shi Y, Li J, Zhang S, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology – mainland China subset analysis of the PIONEER study. PLoS One. 2015;10:e0143515. doi:10.1371/journal.pone.014351526599344
   PubMed Web of Science ®Google Scholar
• Liu GE. China Guidelines for Pharmacoeconomic Evaluations. 1st ed. Beijing: Sciencepress; 2011.
   Google Scholar
• Carroll K. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials. 2003;24:682–701. doi:10.1016/S0197-2456(03)00072-214662274
   PubMedGoogle Scholar
• Diaby V, Adunlin G, Montero AJJP. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32:101–108. doi:10.1007/s40273-013-0123-924338265
   PubMed Web of Science ®Google Scholar
• Zeng X, Peng L, Li J, et al. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the chinese health care system. Clin Ther. 2013;35:54–65. doi:10.1016/j.clinthera.2012.12.01323328269
   PubMed Web of Science ®Google Scholar
• Zhao LY, Zhou ML, Zhi-Gang LU, et al. Pharmacoeconomic evaluation of two first-line therapies for advanced non-small cell lung cancer. Chin J New Drugs Clin Remedies. 2012;31:677–681. [in Chinese].
   Google Scholar
• Zeng X, Li J, Peng L, et al. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis. Asia Pac J Clin Oncol. 2014;9:e88881.
   Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13:e195–e203. doi:10.1111/ajco.1247726990789
   PubMed Web of Science ®Google Scholar
• Xu J, Jin B, Chu T, et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China. Lung Cancer. 2016;96:87–92. doi:10.1016/j.lungcan.2016.01.01827133756
   PubMed Web of Science ®Google Scholar
• Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol. 2017;143:783–791. doi:10.1007/s00432-016-2326-x28215027
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Shafrin J, Hou N, et al. Predicting real-world effectiveness of cancer therapies using overall survival and progression-free survival from clinical trials: empirical evidence for the ASCO value framework. Value Health. 2017;20(7):866–875. doi:10.1016/j.jval.2017.04.00328712615
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer; 2014 Available from: https://www.nice.org.uk/guidance/ta310 Accessed 318, 2018.
   Google Scholar
• Tan PT, Aziz MIA, Pearce F, et al. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective. BMC Cancer. 2018;18:352. doi:10.1186/s12885-018-4223-y29587666
   PubMed Web of Science ®Google Scholar
• Chouaid C, Luciani L, LeLay K, et al. Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non-small cell lung cancers. J Thorac Oncol. 2017;12:1496–1502. doi:10.1016/j.jtho.2017.07.01328751244
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84. doi:10.1186/1477-7525-6-8418939982
   PubMed Web of Science ®Google Scholar
• MacEwan JP, Doctor J, Muliqan K, et al. The value of progression-free survival in metastatic breast cancer: results from a survey of patients and providers. MDM Policy Pract. 2019;4(1):1–14. doi:10.1177/2381468319855386
   Google Scholar
• Shafrin J, Schwartz TT, Okoro T, et al. Patient versus physician valuation of durable survival gains: implications for value framework assessments. Value Health. 2017;20(2):217–223. doi:10.1016/j.jval.2016.11.02828237198
   PubMed Web of Science ®Google Scholar
• Larry Jameson J, Longo DLJO, Survey G. Precision medicine – personalized, problematic, and promising. N Engl J Med. 2015;70:612–614.
   Google Scholar
• Xiaohui Z, Jianhe L, Liubao P, et al. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-markov model analysis. PLoS One. 2014;9:e88881. doi:10.1371/journal.pone.008888124586426
   PubMed Web of Science ®Google Scholar
• Beauchemin C, Letarte N, Mathurin K, et al. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. J Med Econ. 2016;19:619–629. doi:10.3111/13696998.2016.115143126850287
   PubMed Web of Science ®Google Scholar